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Editorial 
Asthma and chronic bronchitis: similarities and 
differences 
Despite numerous attempts, asthma and chronic 
bronchitis have yet to be characterized fully and their 
symptoms remain to be defined completely. In 1959, 
the Ciba Symposium proposed the use of the term 
‘chronic airflow obstruction’ (CAO) to describe 
diseases with a chronic reduction in expiratory flow 
as defined in a specific manner (1). In this document, 
‘asthma refers to the condition of subjects with 
widespread constriction of the bronchial airways 
which may change in severity over short periods of 
time, either spontaneously or under treatment, and 
is not due to cardiovascular disease’. In 1962, the 
American Thoracic Society (2) defined asthma, 
emphysema and chronic bronchitis in basically 
similar terms, but this statement included ‘increased 
airway responsiveness’ in its definition of asthma and 
noted that some asthmatics, particularly those who 
have had asthma for many years, may have persistent 
airtlow obstruction. However, these definitions, 
which remain similar to the description of asthma 
recorded by Floyer some 300 years ago, are still 
based on clinical and functional terms and do not 
allow the characterization of all patients for a variety 
of reasons. Wheezing is the most common symptom 
reported by asthmatics, but it is also a very common 
symptom reported by smokers, and increased airway 
responsiveness is clearly associated with a lower level 
of pulmonary function in asthmatics or smokers. 
Some patients with asthma show poor reversibility 
(3) whereas others with chronic bronchitis have good 
reversibility of the airways (4,5). Moreover, a subset 
of patients presents with obstruction of the airways 
due to various components including asthma, emphy- 
sema and/or chronic bronchitis (6), thus increasing 
the complexity of the definition of chronic obstruc- 
tive pulmonary diseases. In an attempt to improve 
the characterization of asthma, the International 
Consensus Report of 1992 on the diagnosis and 
management of asthma included ‘inflammation’ in 
its definition and proposed that eosinophils and 
mast cells were prominent inflammatory cells (7). 
However, mast cells and eosinophils are found 
in other bronchial diseases including chronic 
bronchitis (8). 
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Chronic airllow obstruction represents a hetero- 
geneous group of diseases among which allergy and 
cigarette smoking are two major causative factors (9). 
In 1961, Orie et al. proposed the so-called ‘Dutch 
hypothesis’ and suggested that, to a considerable 
extent, hyper-reactivity and allergy explained the 
clinical picture of bronchitis and asthma which 
merely represent different patterns of the same con- 
ditions (10). There is a wide range of pulmonary 
reactions in response to environmental factors such 
as cigarette smoke or allergy. Although smoking is a 
major cause of chronic bronchitis, a large proportion 
of smokers never present with symptoms of chronic 
bronchitis. Chronic mucous secretion induced by 
tobacco smoke can occur with normal pulmonary 
function and has no predictive power in explaining 
decline. Although smokers have enlargement of the 
mucous gland, there is an overlap with non-smokers, 
and a similar overlap occurs in patients with bron- 
chitis and a control group (11). Asthma shows an 
even greater spectrum of response since allergy is a 
predominant trigger in children and young adults, 
whereas in most patients developing asthma in adult- 
hood the causes are poorly characterized and allergy 
does not appear to be a major factor. Finally, occu- 
pational exposure and air pollution are likely to 
modify the inflammation of the airways of normal 
subjects or patients with CA0 considerably and to 
alter the natural course of CAO. 
Classification of CA0 may be based on the site and 
the nature of the obstructing lesions. It is rare that 
only one type of lesion is present, but one type may 
often predominate. Post-mortem examinations have 
revealed that both large and small airways are 
involved in asthma and the airway surface epithelium 
is fragile; pseudo-thickening of the reticular layer 
beneath the epithelial basal lamina, bronchial vessel 
congestion and oedema associated with an inflam- 
matory infiltrate including ‘activated’ lympho- 
cytes, eosinophils, macrophages and mast cells 
are observed. Moreover, there is enlargement of 
bronchial smooth muscle and mucous glands (12). In 
chronic bronchitis, a disease of large airways, an 
increase in smooth muscle and mucous glands occurs 
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in the airways, the latter being associated with 
chronic mucus hypersecretion. Inflammation of the 
small airways (bronchiolitis) occurs in about 15% 
of cigarette smokers and is an important cause of 
irreversible airflow obstruction (13). Goblet cell 
metaplasia is a reflection of chronic inflammation of 
the small airways and, together with intralumenal 
mucous, is an important feature of bronchiolitis. 
Permanent narrowing of the small airways presum- 
ably results from inflammation with consequent 
fibrosis, while functional narrowing results from the 
release of inflammatory mediators (11). 
Inflammation of the airways can either be studied 
at post mortem or by using bronchoscopy and 
combining bronchial biopsies with bronchoalveolar 
lavage (BAL) (14). Biopsies directly evaluate the 
inflammatory cells present and airway damage, but 
as they are carried out on large airways, they do not 
provide reliable quantitative data and cannot ident- 
ify the possible heterogeneity of airway lesions. 
Although BAL has its own drawbacks, it indirectly 
reflects the inflammation of the airways, provides 
information on a greater part of the airways, and 
is quantitative. The analysis of inflammation of 
the airways in various CA0 diseases using BAL 
and biopsies has improved our knowledge, but it 
has also served to demonstrate the complexity and 
heterogeneity of these diseases. 
In chronic bronchitis, conventional histological 
methods have shown that epithelial metaplasia and 
inflammation are more associated with neutrophils 
and macrophages (11,15) than eosinophils. These 
cells have not been consistently observed in the 
airways of chronic bronchitis patients (16), and there 
is no correlation between the presence of these cells 
and either reversibility of the airways after inhalation 
of /?-agonists or non-specific bronchial hyper- 
reactivity (17). Most of these studies are difficult to 
interpret completely since they were performed using 
conventional histology, and not the immuno- 
histochemistry techniques that have been shown 
to improve the characterization of cells in the air- 
ways. Bronchoalveolar lavage studies carried out 
in patients with chronic bronchitis showed an 
increased number of total cells and of neutrophils 
in comparison with normal subjects (l&19). 
Neutrophils and eosinophils have been studied in 
the airways of asthmatics and chronic bronchitis 
patients using immunohistochemistry and the 
measurement of eosinophil-derived (ECP: eosinophil 
cationic protein) and neutrophil-derived (MPO: 
myeloperoxidase) mediators in BAL fluid (20). 
Patients with chronic bronchitis were carefully 
selected to differentiate them from asthmatics. None 
of them were allergic nor presented improvement of 
FEV, after inhalation of /&-agonists. An increased 
number of eosinophils was observed in the BAL fluid 
and bronchial biopsies of patients with asthma and 
chronic bronchitis in comparison with normal sub- 
jects. However, release of ECP was only observed 
in the asthmatic subjects. Neutrophils were not 
increased in bronchial biopsies of asthmatic and 
chronic bronchitis patients, but in the BAL fluid 
from patients suffering from chronic bronchitis, they 
were increased both in number and the state of 
activation as indicated by higher levels of MPO. The 
presence of an eosinophilic inflammation in the air- 
ways of chronic bronchitis patients indicates that 
asthma is not the only bronchial disease associated 
with eosinophilic inflammation. Linden et al. (21) 
studied the BAL fluid composition from smokers 
with obstructive and non-obstructive chronic 
bronchitis and found an elevated level of both MPO 
and ECP. Moreover, in contrast to the study of 
Lacoste et al. (20), they showed a significant corre- 
lation between MPO or ECP levels and FEV,. In 
another study, the present authors examined the 
reversibility of airways obstruction of patients with 
obstructive chronic bronchitis after a course of 
120 mg prednisolone daily for 10 days. In 12/27 
patients, a significant improvement of FEV, (over 
15% from baseline or 190 ml) was observed and all 
patients with reversibility had detectable levels of 
ECP in the BAL fluid. On the other hand, most 
patients who did not improve their FEV, had un- 
detectable ECP levels in the BAL fluid (8). These data 
suggest that eosinophilic inflammation may be an 
important feature of some patients with chronic 
bronchitis. This study should be extended in order to 
better understand the links and/or overlaps between 
asthma and chronic bronchitis, and to attempt to 
define which patients may be suitable candidates for 
corticosteroid treatment. 
T-cells have been implicated in the regulation of 
inflammation in asthma (22). In chronic bronchitis, 
infiltration of T-cells has also been observed both 
in the epithelium and the submucosa (23,24). The 
relative proportions of CD4 and CD8 positive cells 
were similar in bronchitic and control subjects. Sub- 
jects with chronic bronchitis also exhibited an 
increased expression of the markers for lymphocyte 
activation (CD25 positive cells) and an increased 
number of very late activation antigen (VLA-1) 
positive cells (24). Cytokines present in the mucosa 
of chronic bronchitis patients are still not character- 
ized completely but it appears that IL-5-positive 
cells can be found (Miiller et al., unpubl. results), 
therefore explaining the eosinophilic inflammation. 
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Macrophages are found in increased numbers in 
the biopsies of both asthmatic (25) and chronic 
bronchitis patients (24). 
The epithelium is fragile and often shed in asthma 
(26) whereas it is often metaplastic in chronic 
bronchitis (12) and in smokers (27). Metaplasia 
consists of patches of squamoid non-polarized 
stacked cells which have lost their contact with the 
basal lamina, with or without nuclear atypia. A 
significant correlation was observed between cell 
proliferation [assessed by proliferative cell nuclear 
antigen (PCNA) immunoreactivity] and the number 
of cigarettes smoked or the grade of metaplasia 
(28). The balance between differentiation and pro- 
liferation may be impaired in chronic bronchitis. 
They may be due to the stimulation of extracellular 
growth factors by cigarette smoke and their action 
on specific membrane-bound receptors resulting in 
switching-on the cascade of intracellular processes 
(29). Platelet-derived growth factor may be one of 
these factors since it is expressed on epithelial cells 
of chronic bronchitis patients (30). Regeneration 
of epithelium involves cell differentiation and/or 
proliferation, leading to different patterns of re- 
epithelialization, which may be normal in asthmatic 
patients and metaplastic in those with chronic 
bronchitis. 
The inflammation of the airways of patients with 
chronic bronchitis or asthma is often similar and 
there is possibly more heterogeneity among CA0 
diseases than expected. In particular, asthma is not 
the only CA0 disease with eosinophilic inflamma- 
tion. Eosinophilic inflammation of the airways of 
patients with chronic bronchitis may explain the 
reversibility of the obstruction under corticosteroids 
and the bronchial hyper-reactivity demonstrated in 
some patients. The heterogeneity of inflammation of 
the airways may be increased by co-factors such as 
pollutants and occupational agents. It seems, there- 
fore, that more data are needed to better understand 
the increasingly complex situation of CAO. 
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